Clinical Trials
2
Active:0
Completed:0
Trial Phases
1 Phases
Phase 1:2
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials
Phase 1
2 (100.0%)CD19 Targeted CAR T Cell Therapy in Patients With Relapsed/ Refractory B Cell Acute Lymphoblastic Leukaemia (ALL)
Phase 1
- Conditions
- Refractory B Cell Acute Lymphoblastic Leukemia (ALL)Relapsed B Cell Acute Lymphoblastic Leukemia (ALL)
- Interventions
- Biological: CD19 CAR engineered autologous T-cells
- First Posted Date
- 2020-12-04
- Last Posted Date
- 2021-03-19
- Lead Sponsor
- Sabz Biomedicals
- Target Recruit Count
- 22
- Registration Number
- NCT04653493
- Locations
- 🇮🇷
Gene therapy research center, Shariati hospital, Tehran university of medical sciences, Iran, Tehran, Iran, Islamic Republic of
🇮🇷Research Institute for Oncology- Hematology and Cell Therapy (RIOHCT), Tehran University of Medical Sciences, Tehran, Iran, Islamic Republic of
Autologous Killer Cell Therapy in Colon Cancer Patients
Phase 1
- Conditions
- Colon Cancer Stage IV
- First Posted Date
- 2017-11-06
- Last Posted Date
- 2021-03-15
- Lead Sponsor
- Sabz Biomedicals
- Target Recruit Count
- 20
- Registration Number
- NCT03329664
- Locations
- 🇮🇷
Gene Therapy Research Center, Digestive Disease Research Institute, Tehran University of Medical Sciences, Tehran, Iran, Islamic Republic of
News
No news found